Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
Rhea-AI Summary
Palisade Bio (NASDAQ: PALI) announced that two abstracts featuring its lead program PALI-2108 for ulcerative colitis treatment have been selected for presentation at Digestive Disease Week (DDW) 2025, scheduled for May 3-6 in San Diego.
The first presentation, focusing on bioinformatic approaches to PALI-2108 treatment in ulcerative colitis, will explore anti-fibrotic efficacy potential with local PDE4 inhibition in intestinal fibrosis. This session is scheduled for May 4, 2025.
The second abstract, recognized as a Poster of Distinction and rated in the top 10% of all AGA abstracts, will present findings on PALI-2108's colon-specific PDE4 inhibitor prodrug properties. The research demonstrates the drug's bioactivation in the colon, its dose-dependent reduction of colon tissue PDE4B, increased c-AMP, and TNF-α suppression in a mouse colitis model. This presentation is scheduled for May 5, 2025.
Positive
- Abstract rated in top 10% of AGA submissions, demonstrating strong scientific recognition
- Preclinical data shows multiple positive mechanisms of action for PALI-2108
- Selection for presentation at major industry conference increases visibility
Negative
- Research still in preclinical stage with no human trial data presented
- No efficacy or safety data in human patients reported
PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top
Carlsbad, CA, March 12, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to present data from its lead program PALI-2108 for the treatment of ulcerative colitis at Digestive Disease Week® (DDW) 2025 being held May 3–6, in San Diego, California.
Participation details are as follows:
Poster Presentation
Session Title: Transcriptional, Epigenetic and Genetic Regulation of GI Function and Disease
Session Date & Time: May 4, 2025 from 12:30 PM to 1:30 PM PDT
Title: A BIOINFORMATIC APPROACH TO PALI-2108 TREATMENT IN ULCERATIVE COLITIS REVEALS THE POTENTIAL FOR ANTI-FIBROTIC EFFICACY WITH LOCAL PDE4 INHIBITION IN INTESTINAL FIBROSIS
DDW Poster of Distinction – Poster Presentation
Session Title: In Vivo Models of Gastrointestinal Disorders
Session Date & Time: May 5, 2025 from 12:30 PM to 1:30 PM PDT
Title: PALI-2108, A COLON-SPECIFIC PDE4 INHIBITOR PRODRUG, IS BIOACTIVATED IN THE COLON AND REDUCES COLON TISSUE PDE4B IN A DOSE-DEPENDENT MANNER, INCREASING C-AMP AND SUPPRESSING TNF-Α IN A MOUSE MODEL OF COLITIS
Digestive Disease Week is a leading forum for experts in the field of gastroenterology bringing together clinicians, researchers, and pharmaceutical leaders to discuss the latest advancements in treating digestive diseases. For more information about Digestive Disease Week please visit the conference website.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the Company’s Phase 1b/2a clinical study, indications and anticipated benefits of PALI-2108 and the expected timing of the release of topline data from the Phase 1b/2a clinical study. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company is heavily dependent on the success of PALI-2108, which is in the early stages of clinical development and may not successfully progress through clinical development or receive regulatory approval; preliminary clinical study results or the results from earlier preclinical studies may not be predictive of final or future results and unexpected adverse side effects or inadequate efficacy of PALI-2108 may limit its development, regulatory approval and/or commercialization; the Company needs to raise significant additional funds to support its operations and the continued development of PALI-2108; the timing and outcome of the Company’s current and anticipated clinical studies related to its product candidates; indications of use and estimates about the size and growth potential of the markets for the Company’s product candidates, and its ability to serve those markets, including any potential revenue generated; the Company’s ability to maintain the Nasdaq listing of its securities; the Company’s ability to compete effectively in a competitive industry; the Company’s ability to identify and qualify manufacturers to provide API and manufacture drug product; the Company’s ability to enter into commercial supply agreements; the Company’s ability to attract and retain key scientific or management personnel; the accuracy of the Company’s estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and the impact of any global event on the Company’s business, and operations, and supply. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
What are the key findings of PALI-2108 in the mouse colitis model presented at DDW 2025?
Why was Palisade Bio's PALI-2108 abstract selected as a Poster of Distinction at DDW 2025?
What therapeutic areas is PALI-2108 being developed for?
When and where will Palisade Bio present their PALI-2108 research at DDW 2025?
